FP599VITAMIN D THERAPY AND MORTALITY IN HEMODIALYSIS PATIENTS

Abstract

throughout study followup. No difference in ESA consumption was noted [median(IQR): 10(6-15) vs 6(4-9) 10^3 UI/week for standard vs intense PTH control study arm]. A post-hoc analysis also excluded an overall association of PTH lowering and ESA use. Although this is a RCT with a pre-specified sample size, the open-label design and the poor protocol adherence of the attending physicians should be considered when study results are analyzed CONCLUSIONS: The OPTIMAL ESRD TREATMENT study fail to demonstrate an association between PTH and anemia control. Future endeavors are needed to elucidate whether current results are due to the poor protocol adherence noted in the study Table 1 Variable Intensive Standard Age (years) 68(11) 64(21) Dialysis vintage (month) 42[17-83] 47[21-73] Women (%) 28 36 Systolic Blood Pressure (mmHg) 146(30) 145(24) Diastolic Blood Pressure (mmHg) 72(12) 70(12) Hypertension(%) 84 76 Diabetes(%) 32 44 Coronary artery disease (%) 28 16 Cerbrovascular disease (%) 20 16 PTH (pg/ml)